Kates R E, Yee Y G, Kirsten E B
Clin Pharmacol Ther. 1987 Sep;42(3):305-11. doi: 10.1038/clpt.1987.152.
The effect of propafenone on the pharmacokinetics and pharmacologic effects of warfarin was studied in healthy normal male volunteer subjects. Each drug was administered alone for 1 week followed by a combined administration for 1 additional week. Blood samples were analyzed for propafenone and warfarin concentrations and the effect of each treatment on the prothrombin time was assessed. The concurrent administration of warfarin did not produce any changes in the absorption or disposition kinetics of propafenone. Concurrent propafenone administration did lead to a reduction in the clearance of warfarin, resulting in an average increase of 38% in the mean steady-state plasma warfarin concentration. During the combined therapy phase, the prothrombin time increased significantly (P less than 0.01) from the "warfarin alone" phase. We conclude from this study that the concomitant administration of propafenone and warfarin may lead to an enhanced anticoagulant effect that may require a reduction in the warfarin dose.
在健康正常男性志愿者中研究了普罗帕酮对华法林药代动力学和药理作用的影响。每种药物单独给药1周,随后联合给药1周。分析血样中普罗帕酮和华法林的浓度,并评估每种治疗对凝血酶原时间的影响。华法林的同时给药未使普罗帕酮的吸收或处置动力学发生任何变化。普罗帕酮的同时给药确实导致华法林清除率降低,导致平均稳态血浆华法林浓度平均增加38%。在联合治疗阶段,凝血酶原时间较“单独使用华法林”阶段显著增加(P<0.01)。我们从这项研究得出结论,普罗帕酮和华法林的联合给药可能导致抗凝作用增强,这可能需要降低华法林剂量。